Apex Biotechnology (TPE:1733) Other Stockholders Equity: NT$552 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1733 Apex Biotechnology Corp TPE:1733
80 GF Score
Price NT$31.15
GF Value NT$30.04
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Apex Biotechnology Other Stockholders Equity?

Apex Biotechnology TPE:1733 -1.58% 80 Other Stockholders Equity is NT$552 Mil as of Dec. 2025. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$30.04 (Fairly Valued). The stock has 2 warning signs investors should review.

Apex Biotechnology's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$552 Mil.

Apex Biotechnology's quarterly Other Stockholders Equity increased from Jun. 2025 (NT$549 Mil) to Sep. 2025 (NT$551 Mil) and increased from Sep. 2025 (NT$551 Mil) to Dec. 2025 (NT$552 Mil).

Apex Biotechnology's annual Other Stockholders Equity increased from Dec. 2023 (NT$526 Mil) to Dec. 2024 (NT$540 Mil) and increased from Dec. 2024 (NT$540 Mil) to Dec. 2025 (NT$552 Mil).

Apex Biotechnology Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Other Stockholders Equity Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 479.50 506.96 525.90 539.76 552.22

Apex Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 539.76 540.26 549.41 550.91 552.22
TPE:1733
80GF Score
Apex Biotechnology Corp TPE:1733
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apex Biotechnology Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$552 Mil mean?
Apex Biotechnology (TPE:1733) has a Other Stockholders Equity of NT$552 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Apex Biotechnology and its competitors.
Is Apex Biotechnology's Other Stockholders Equity too high?
Apex Biotechnology's current Other Stockholders Equity is NT$552 Mil. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Other Stockholders Equity compare to VRTX and REGN?
Apex Biotechnology's Other Stockholders Equity of NT$552 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Other Stockholders Equity is NT$552 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.04, compared to a current price of NT$31.15 — trading 3.7% above its estimated fair value. The current Other Stockholders Equity is NT$552 Mil. Apex Biotechnology's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Other Stockholders Equity is NT$552 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued. The current stock price of NT$31.15 is trading 3.7% above its estimated GF Value™ of NT$30.04. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Other Stockholders Equity: NT$552 Mil
  • GF Value™: NT$30.04 vs. price of NT$31.15 (3.7% above fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score

Get the complete analysis for TPE:1733

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.15
Price
NT$30.04
GF Value